- Home
- NXN vs STTK Comparison
NXN vs STTK Comparison
Compare NXN & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXN
- STTK
- Stock Information
- Founded
- NXN 1992
- STTK 2016
- Country
- NXN United States
- STTK United States
- Employees
- NXN N/A
- STTK N/A
- Industry
- NXN Trusts Except Educational Religious and Charitable
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- NXN Finance
- STTK Health Care
- Exchange
- NXN Nasdaq
- STTK Nasdaq
- Market Cap
- NXN 45.3M
- STTK 37.6M
- IPO Year
- NXN N/A
- STTK 2020
- Fundamental
- Price
- NXN $11.56
- STTK $0.82
- Analyst Decision
- NXN
- STTK Hold
- Analyst Count
- NXN 0
- STTK 4
- Target Price
- NXN N/A
- STTK $3.00
- AVG Volume (30 Days)
- NXN 9.7K
- STTK 396.2K
- Earning Date
- NXN 01-01-0001
- STTK 07-31-2025
- Dividend Yield
- NXN 4.23%
- STTK N/A
- EPS Growth
- NXN N/A
- STTK N/A
- EPS
- NXN 0.24
- STTK N/A
- Revenue
- NXN N/A
- STTK $4,606,000.00
- Revenue This Year
- NXN N/A
- STTK N/A
- Revenue Next Year
- NXN N/A
- STTK N/A
- P/E Ratio
- NXN $48.42
- STTK N/A
- Revenue Growth
- NXN N/A
- STTK 69.65
- 52 Week Low
- NXN $10.64
- STTK $0.69
- 52 Week High
- NXN $12.45
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- NXN 53.45
- STTK 37.21
- Support Level
- NXN $11.53
- STTK $0.77
- Resistance Level
- NXN $11.68
- STTK $1.14
- Average True Range (ATR)
- NXN 0.13
- STTK 0.09
- MACD
- NXN 0.02
- STTK -0.03
- Stochastic Oscillator
- NXN 49.23
- STTK 9.88
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.